Lexicon announces publication of Telestar study results for Carcinoid Syndrome
NEWS RELEASE FOR IMMEDIATE RELEASE LEXICON ANNOUNCES PUBLICATION OF TELESTAR STUDY RESULTS FOR TELOTRISTAT ETHYL IN THE JOURNAL OF CLINICAL ONCOLOGY Results from Pivotal Phase 3 Clinical Study of Telotristat Ethyl Show Clinical Benefit in Patients with Carcinoid Syndrome The Woodlands, Texas, October 31, 2016 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the Journal of Clinical Oncology published detailed results from Lexicon’s pivotal Phase 3 TELESTAR clinical study